China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to RMB 200 million (USD 27.3 million) in a Series A financing round led by Sansure, Sanway Spring, and Voyagers Capital. The funds will be directed towards research and development and the construction of an industrialization base for the company’s next-generation molecular diagnostic point-of-care testing (POCT) product.
About Shengwei Kunteng and Its Q-POC Instrument
Founded in 2023, Shengwei Kunteng is known for its Q-POC instrument, a fast, easy-to-use, and portable molecular diagnostic device that has obtained the CE mark. The technology platform supports ultra multi-target detection, which can be completed within half an hour at the earliest. This capability enables a wide range of molecular diagnostic tests, including complex infectious diseases pathogen joint detection, drug resistance gene screening, personalized drug gene detection, and cancer early screening.
Expanding Molecular Diagnostic Capabilities
The Series A financing will significantly bolster Shengwei Kunteng’s ability to advance its molecular diagnostic technologies and expand its market presence. The investment underscores the potential of the company’s innovative solutions in addressing various diagnostic needs efficiently and effectively.-Fineline Info & Tech
